Cellosaurus logo
expasy logo

Cellosaurus AB0023 (CVCL_C6IJ)

[Text version]
Cell line name AB0023
Accession CVCL_C6IJ
Resource Identification Initiative To cite this cell line use: AB0023 (RRID:CVCL_C6IJ)
Comments Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized simtuzumab (GS 6624) therapeutic antibody that was investigated in a failed phase 2 clinical study for the treatment of idiopathic pulmonary fibrosis.
Characteristics: The monoclonal produced by this hybridoma allosterically inhibits the activity of LOXL2 (PubMed=20439985).
Monoclonal antibody isotype: Not specified.
Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2 (Note=Also reacts with mouse).
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_4032 (P3X63Ag8.653)
Category Hybridoma
Publications

PubMed=20439985; DOI=10.1074/jbc.M109.094136
Rodriguez H.M., Vaysberg M., Mikels A., McCauley S.A., Velayo A.C., Garcia C.A., Smith V.
Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor.
J. Biol. Chem. 285:20964-20974(2010)

Patent=US8680246
McCauley S.A., Rodriguez H.M., Garcia C.A., Smith V.
Antibodies that bind to lysyl oxidase-like 2 (LOXL2).
Patent number US8680246, 25-Mar-2014

Patent=US10494443
Smith V., Ogg S., Van Vlasselaer P., Barry V.E., Marshall D., Holzer A.K., Rodriguez H.M., Oyasu M., McCauley S.A., Garcia C.A., Hiroko D., Biermann T.
LOX and LOXL2 inhibitors and uses thereof.
Patent number US10494443, 03-Dec-2019

Cross-references
Encyclopedic resources Wikidata; Q116048468
Entry history
Entry creation15-Dec-2022
Last entry update21-Mar-2023
Version number2